The surgical aspects neuroendocrine tumors of pancreas

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

An article dedicated to neuroendocrine tumors of pancreas - the group of malignant and benign formations, least explored in oncoendocrinology, extremely laborious for diagnostics and treatment. Contemporary points of view on questions of topical diagnostics, estimation of tumor morphological characteristics, their differentiation and malignancy, determine effectiveness of treatment of that sort f patients and disease prognosis. Considering of genetic and morphological properties of neuroendocrine tumors of pancreas, the principal method ot treatment is surgical. Contemporary scientific elaborations, dedicated to different aspects of neuroendocrine neoplasms, produce conditions for combination surgical operation with antisecretory, radionuclide and chemotherapy. The combined therapeutic management provide for considerable improvement quality and duration of life patients with such tumors.

About the authors

N. A. Maystrenko

Military Medical Academy; Moscow Regional Scientific and Research Ginicai Institute

Author for correspondence.
Email: shabanov@mail.rcom.ru

член-корреспондент РАМН

Russian Federation, St. Petersburg; Moscow

S. F. Basos

Military Medical Academy; Moscow Regional Scientific and Research Ginicai Institute

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; Moscow

Al. A. Kurygin

Military Medical Academy; Moscow Regional Scientific and Research Ginicai Institute

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; Moscow

L. E. Gurevich

Military Medical Academy; Moscow Regional Scientific and Research Ginicai Institute

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg; Moscow

References

  1. Гуревич Л. Е. Диагностика нейроэндокринных опухолей желудочно-кишечного тракта/ Л. Е. Гуревич // Практ. онкол. 2005. Т. 6. № 4. С. 193-201.
  2. Егоров А. В., Кузин Н. М., Ветшев П. С. и др. Спорные и нерешенные вопросы диагностики и лечения гормонопродуцирующих нейроэндокринных опухолей поджелудочной железы // Хирургия. 2005. № 9. С. 19-24.
  3. Егоров А. В., Кузин Н. М. Вопросы диагностики нейроэндокринных опухолей поджелудочной железы // Практ. онкол. 2005. Т. 6. № 4. С. 206-212.
  4. Калинин А. П., Трофимов В. М., Нечай А. И. Современное представление о гормонально-активных опухолях поджелудочной железы: диагностика, лечение // Хирургия и диабет. Гормонально-активные опухоли поджелудочной железы. Саратов, 1993. С. 98-107.
  5. Кузин Н. М., Егоров А. В. Нейроэндокринные опухоли поджелудочной железы: Руководство. М., 2001.208 с.
  6. Кузин Н. М., Егоров А. В., Кондрашин С. А. и др. Диагностика и лечение гастринпродуцирующих опухолей поджелудочной железы // Клин. мед. 2002. №З.Р. 71-76.
  7. Майстренко Н. А., Басос С. Ф. Инсулинома//Хирургическая эндокринология. СПб., 2004. С. 641-715.
  8. Майстренко Н. А., Басос С. Ф., Курыгин А. А., Хижа В. В. Клинико-морфологическое обоснование хирургического лечения нейроэндокринных опухолей поджелудочной железы. Анналы хирургической гепатологии. М., 2006. Т. 11. № 3. С. 135.
  9. Майстренко Н. А., Басос С. Ф., Хижа В. В. Результаты хирургического лечения органического гиперинсулинизма // Современные аспекты хирургической эндокринологии: Материалы XX Рос. симп. по хир. эндокрин. Смоленск, 2002. С. 239-240.
  10. Майстренко Н. А., Басос С. Ф., Юшкин А. С., Хижа В. В. Эффективность методов диагностики и пути улучшения результатов хирургического лечения органического гиперинсулинизма // Современные аспекты хирургической эндокринологии. Челябинск, 2000. С.265-267.
  11. Органический гиперинсулинизм / Под ред. проф. Н. А. Майстренко. СПб., 2004. 128 с.
  12. Майстренко Н. А., БасосС. Ф., Калашников С. А. и др. Опухоли апудсистемы поджелудочной железы // Рос. журн. гастроэнтерол., гепатол. и колопро- ктол. 1996. № 4. С. 154.
  13. Трофимов В. М. Трудные вопросы диагностики и хирургической тактики у больных с гиперинсулинизмом // Актуальные вопросы современной эндокринологии. СПб., 2001. С. 209.
  14. Akerstrom G., Hessman О., Hellman Р., Skogseid В. Pancreatic tumours as part of the MEN-1 syndrome // Best Pract. Res. Clin. Gastroenterol. 2005. Vol. 19. P. 819-830.
  15. Alexander H. R., Fraker D. L., Norton J. A. et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger - Ellison syndrome И Ann. Surg. 1998. Vol. 228 (2). P. 228-238.
  16. Altimari A. E, Badrinath K., Reisel H. J., Prinz R. A. DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors//Surgery. 1987. Vol. 102. P. 1009-1017.
  17. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options И Best Pract. Res. Clin. Gastroenterol. 2005. Vol. 19. P. 491-505.
  18. Arnold R., Rinke A., Schmidt C., Hofbauer L. Endocrine tumours of the gastrointestinal tract: chemotherapy // Best Pract. Res. Clin. Gastroenterol. 2005. Vol. 19. P. 649-656.
  19. BuscombeJ. R., Caplin M. E., HilsonA. J. Long-term efficacy of high-activity 111 in-pentetreotide therapy in patients with disseminated neuroendocrine tumors П J. Nucl. Med. 2003. Vol. 44. P. 1-6.
  20. Chamberlain R. S., Canes D., Brown К T.et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? // J. Am. Coll. Surg. 2000. Vol. 190. P. 432-445.
  21. Clark О. H, AjaniJ., Benson A. B. et al. Neuroendocrine tumors // J. Natl. Compr. Cane. Netw. 2006. Vol. 4. P. 102-138.
  22. De Jong M., Breeman W.A., Valkema R. etal. Combination radionuclide therapy using 177Lu- and Y-labeled somatostatin analogs И J. Nucl. Med. 2005. Vol. 46 (Suppl. 1). P. 13S-17S.
  23. Doherty G. M. Pancreatic tumors in multiple endocrine neoplasia type 1 И World J. Surg. 2006. [Epub, ahead of print.]
  24. Eriksson B., Arnberg H., Lindgren P. G. et al. Neuro¬endocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients // J. Int. Med. 1990. Vol. 228. P. 103-113. -
  25. ErikssonB., OrleforsH., ObergK. etal. Developments in PET for the detection of endocrine tumours // Best Pract. Res. Clin. Endocrinol. Metab. 2005. Vol. 19. P. 311-324.
  26. Esni E, Staffers D. A., Takeuchi T., Leach S. D. Origin of exocrine pancreatic cells from nestin-positive pre¬cursors in developing mouse pancreas H Meeh. Dev. 2004. Vol. 121. P. 15-25.
  27. Granberg D., Wilander E., Stridsberg M. etal. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids // Gut. 1998. Vol. 43 (2). P. 223-228.
  28. Grant C. S. Insulinoma H Best Pract. Res. Clin. Gastroenterol. 2005. Vol. 19. P. 783-798. Ellison E. C., Sparks J., Verducci J. S. et al. 50-year appraisal of gastrinoma: recommendations for staging and treatment H J. Am. Coll. Surg. 2006. Vol. 202. P. 897-905.
  29. Gumbs A. A., Moore P. S., Falconi M. et al. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms // J. Surg. Oncol. 2002. Vol. 81. P. 45-53, discussion 54.
  30. Hessman O., Lindberg D., Einarsson A. et al. Genetic alterations on 3p, llql3, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors//Genes Chromosomes Cancer. 1999. Vol. 26. P. 258-264.
  31. Kaltsas G. A., Mukherjee J. J., Grossman A. B. The val¬ue of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours // Ann. Oncol. 2001. Vol. 12 (Suppl. 2). P S47-S50.
  32. Kaltsas G. A., Papadogias D., Makras P, Gross¬man A. B. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues // Endocr. Relat. Cancer. 2005. Vol. 12. P. 683-699.
  33. Kloppel G., SolciaE., Capella C„ HeitzP. U. Classification of neuroendocrine tumours // Itai. J. Gastroenterol. Hepatol. 1999. Vol. 31 (Suppl. 2). P. Slll- S116.
  34. Kouvaraki M. A., Ajani J. A., Hoff P. et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas // J. Clin. Oncol. 2004. Vol. 22. P. 4762-4771.
  35. Kouvaraki M. A., Shapiro S. E., Cote G. J. et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 II World J. Surg. 2006. Vol. 30. P. 643-653.
  36. Krenning E. P., Kwekkeboom D. J., Bakker W. H. et al. Somatostatin receptor scintigraphy with [11 lln-DTPA- D-Phel]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients // Eur. J. Nucl. Med. 1993. Vol. 20. P. 716-731.
  37. Lairmore T. C., Piersall L. D., DeBenedetti M. К et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1)//Ann. Surg. 2004. Vol. 239 (5). P 637-645; discussion 645-647.
  38. Mansour J. C., Chen H. Pancreatic endocrine tumors // J. Surg. Res. 2004. Vol. 120. P. 139-161.
  39. McLean A. M., Fairclough P. D. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours // Best Pract. Res. Clin. Endocrinol. Metab. 2005. Vol. 19. P. 177-193.
  40. Modlin I. М„ Lye К. D., Kidd М. A 5-decade analysis of 13,715 carcinoid tumors // Cancer. 2003. Vol. 97. P. 934-959.
  41. Moertel C. G., Lejkopoulo M., Lipsitz S. et al. Sireptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carci¬noma//N. Engl. J. Med. 1992. Vol. 326. P. 519-523.
  42. NeharD., Lombard-Bohas C., Olivieri S. et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours // Clin. Endocrinol. (Oxf.) 2004. Vol. 60. P. 644-652.
  43. Norton J. A. Surgery and prognosis of duodenal gastrinoma as a duodenal neuroendocrine tumor // Best Pract. Res. Clin. Gastroenterol. 2005. Vol. 19. P. 699-704.
  44. Norton J. A., Fang T. D., Jensen R T. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1 // J. Natl. Compr. Cane. Netw. 2006. Vol. 4. P. 148-153.
  45. Norton J. A., Kivlen M., Li M. et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors //Arch. Surg. 2003. Vol. 138. P 859-866.
  46. Norton J. A., Warren R. S., Kelly M. G. et al. Aggressive surgery for metastatic liver neuroendocrine tumors // Surgery. 2003. Vol. 134. P. 1057-1063, discussion 1063-1065.
  47. Oberg K. Diagnosis and treatment of carcinoid tumors// Expert Rev. Anticancer. Ther. 2003. Vol. 3. P. 863-877,
  48. Oberg K, Eriksson B. Endocrine tumours of the pancreas // Best Pract. Res. Clin. Gastroenterol. 2005. Vol. 19. P. 753-781.
  49. Ohike N„ Morohoshi T. Pathological assessment of pancreatic endocrine tumors for metastatic potential and clinical prognosis // Endocr. Pathol. 2005. Vol. 16. P. 33-40.
  50. Orlefors H., Sundin A., Garske U. et al. Whole-body (ll)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography // J. Clin. En¬docrinol. Metab. 2005. Vol. 90. P. 3392-3400.
  51. Pape U. E, Bohmig M., Berndt V. et al. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center //Ann. NY Acad. Sci. 2004. Vol. 1014. P. 222-233.
  52. PasiekaJ. L., McEwan A. J., RorstadO. The palliative role of 1311-MIBG and 111 In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms//Surgery. 2004. Vol. 136. P. 1218-1226.
  53. Rappeport E. D., Hansen С. P., Kjaer A., Knigge U. Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors // Acta Radiol. 2006. Vol. 47. P. 248-256.
  54. Regitnig P., Spuller E., DenkH. Insulinoma of the pancreas with insular-ductular differentiation in its liver metastasis-indication of a common stem-cell origin of the exocrine and endocrine components // Virchows Arch. 2001. Vol. 438. P. 624-628.
  55. Rigaud G., Missiaglia E., Moore P. S. et al. High reso¬lution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications // Cancer Res. 2001. Vol. 61. P. 285-292.
  56. Rindi G., Capella C., Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract // Q. J. Nucl. Med. 2000. Vol. 44. P. 13-211.
  57. Rosewicz S., Detjen K, Scholz A, von Marschall Z Interferon-alpha: regulatory effects on cell cycle and angiogenesis // Neuroendocrinoiogy. 2004. Vol. 80 (Suppl. 1). P. 85-93.
  58. Sarmiento J. M., Heywood G„ Rubin J. et al. Surgical treatment of neuroendocrine metastases to the liver a plea for resection to increase survival // J. Am. Coll. Surg. 2003. Vol. 197. P. 29-3 7.
  59. Solcia E., Sessa E, Rindi G. et al. Classification and histogenesis of gastroenteropancreatic endocrine tumours И Eur. J. Clin. Invest. 1990. Vol. 20 (Suppl. 1). P. S72-S81.
  60. Solorzano С. C., Lee J. E, Pisters P. Wet al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients // Sur¬gery. 2001. Vol. 130. P. 1078-1085.
  61. Sull iff V. E„ Doppman J. L., Gibril E et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns // J. Clin. Oncol. 1997. Vol. 15. P. 2420-2431.
  62. SywakM. S, PasiekaJ. L, McEwan A. et al. ,3lI-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors // World J. Surg. 2004. Vol. 28. P. 1157-1162.
  63. Teunissen J. J., Kwekkeboom D. J., Krenning E. P. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTAO,Tyr3]octreotate // J. Clin. Oncol. 2004. Vol. 22. P. 2724-2729
  64. Thoeni R E, Mueller-Lisse U. G., Chan ft et al. В Detection of small, functional islet tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity // Radiology. 2000. Vol. 214. P. 483490.
  65. Triponez F, Goudet R, Dosseh D. et al. Is surgery ben¬eficial for MEN1 patients with small (< 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE // World J. Surg. 2006. Vol. 30. P. 654-662; discussion 663-664.
  66. Virgolini /., Traub-Wei dinger T., Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours H Best Pract. Res. Clin. Endocrinol. Metab. 2005. Vol. 19. P. 213-227.
  67. Wick M. R, Graeme-Cook E M. Pancreatic neuroendocrine neoplasms: a current summary of diagnostic, prognostic, and differential diagnostic information // Am. J. Clin. Pathol. 2001. Vol. 115 (Suppl. ). P. S28-S45.
  68. Уи E, Venzon D. J, Serrano J. et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome // J. Clin. Oncol. 1999. Vol. 17 P. 615-630.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.